Amarin (AMRN) Reports Positive Data from MARINE Phase 3 in Reducing LDL
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corporation plc (Nasdaq: AMRN), presents data from Amarin's Phase 3 clinical trial, the MARINE study, in which patients with very high trigylcerides (≥500 mg/dl) treated with 4 grams per day of AMR101 experienced a significant reduction in median placebo-adjusted lipoprotein particle concentrations of total low-density lipoprotein (LDL) and small LDL. The data were presented by Harold Bays, M.D., Medical Director of Louisville Metabolic and Atherosclerosis Research and principal investigator of the MARINE trial, at the American Heart Association's Scientific Sessions in Orlando, Fla.
When looking at lipoprotein particle concentrations and sizes as measured with nuclear magnetic resonance spectroscopy, AMR101 4 grams per day, compared with placebo, significantly reduced median total LDL particle count by 16.3% (P=0.0006), which is an important factor in atherogenesis. This is consistent with, and directly linked to, Amarin's previously reported statistically significant reduction in apolipoprotein B (apo-B) of 8.5% compared to placebo at the 4 grams dose. LDL particle count and apo-B are important risk markers for the prediction of cardiovascular events. Small LDL particle count was reduced by 25.6% (P<0.0001) compared with placebo, which is a common risk factor for cardiovascular events in patients with diabetes. AMR101 2 grams per day, compared with placebo, significantly reduced median small LDL particle count by 12.8% (P <0.05) and reduced median total LDL particle count by 1.1% (NS). Amarin previously reported a non statistically significant reduction in apolipoprotein B (apo-B) of 2.6% compared to placebo at the 2 grams dose. LDL particle size did not change significantly for the 2 or 4 grams doses.
When looking at lipoprotein particle concentrations and sizes as measured with nuclear magnetic resonance spectroscopy, AMR101 4 grams per day, compared with placebo, significantly reduced median total LDL particle count by 16.3% (P=0.0006), which is an important factor in atherogenesis. This is consistent with, and directly linked to, Amarin's previously reported statistically significant reduction in apolipoprotein B (apo-B) of 8.5% compared to placebo at the 4 grams dose. LDL particle count and apo-B are important risk markers for the prediction of cardiovascular events. Small LDL particle count was reduced by 25.6% (P<0.0001) compared with placebo, which is a common risk factor for cardiovascular events in patients with diabetes. AMR101 2 grams per day, compared with placebo, significantly reduced median small LDL particle count by 12.8% (P <0.05) and reduced median total LDL particle count by 1.1% (NS). Amarin previously reported a non statistically significant reduction in apolipoprotein B (apo-B) of 2.6% compared to placebo at the 2 grams dose. LDL particle size did not change significantly for the 2 or 4 grams doses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
